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found that some batches of medium did not stain well even if con-
centrated. In these cases, we generated more medium from a new
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Supplemental Experimental Procedures
Screening for LAR Ligands infection. These protocols were used in the same manner to gener-
ate fusion proteins for DPTP10D, DPTP99A, DPTP69D, DPTP4E,The extracellular domain of LAR (aa 33–1377) fused to a C-terminal
PLAP sequence was cloned into a baculovirus expression vector, LAR-HS1-AP, LAR-HS2-AP, and others.
To detect binding, stage 16 embryos were manually dechorio-pVL1393 (BD Biosciences) [S1, S2]. The LAR signal sequence (aa
1–32) was replaced with the gp67 signal sequence. Baculoviruses nated, transferred to an agar block, and lined up, ventral side up
and anterior at the top. The line of embryos was transferred onto awere generated and used to infect Sf9 cells, and supernatant media
were collected at the appropriate time after infection, as evaluated strip of double-stick tape attached to a SuperFrostPlus glass slide
within a rectangle of wax (about 30  20 mm) laid down by a PAPby measuring fusion protein levels. The fusion proteins were quanti-
pen. The embryos (now dorsal side up) were immediately floodedfied by measuring AP activity as described previously [S3]. Con-
with 1 phosphate-buffered saline (PBS: 1 mM KH2PO4, 155 mMditioned media, containing secreted LAR-AP fusion protein, was
NaCl, 3 mM Na2HPO4-7H2O [pH 7.4]). They were then removed fromincubated with live-dissected embryos. If strong staining was not
the vitelline membrane by cutting through it with a glass needle,observed, we concentrated the media 5–10 with an Amicon con-
transferred onto the glass, and dissected to create a filet. Most ofcentrator. This usually increased staining efficacy; however, we
the PBS was removed, and then 200 l of undiluted LAR-AP fusion
protein supernatant was added with a P1000 at the same time as
the remaining PBS was removed from the opposite corner of theTable S1. Genotypes Tested for LAR-AP Staining
well with another P1000. Fusion protein aliquots were centrifuged
LAR-AP Fusion Protein for 10 min at maximum speed at 4C before addition. This replace-
Staining ment of the PBS by supernatant was done so as to minimize dilution
of the supernatant as much as possible without exposing the em-
CNS Muscle
bryos to air. The embryos were incubated for 1–2 hr at room temper-
Axons Attachment Sites ature in a moisturized chamber. LAR-AP was then exchanged for
5% formaldehyde in 1 PBS without prewashing (fix was addedKey Df Crosses
simultaneously with removal of the supernatant as described above
Df(2R)C4  Df(2R)Egfr5   for the PBS/supernatant exchange, then the slides were washed
Df(2R)AA21  Df(2R)Egfr5  — 3 more with larger volumes of fix). The embryos were fixed for 45
min to 1.5 hr at room temperature. The fix was then exchanged forMutants
1 PBS (3 washes of 2 ml each) and then for PBT (1 PBS, 1
SdcDf48  — mg/ml BSA, 0.05% Triton-X100; 3 more washes). Embryos were
Sdc10608  — blocked in PBT with 5% normal goat serum (PBTNGS) for 10–30
SdcKG06163  — min at room temperature. Embryoswere incubatedwith 200l rabbit
SdcDf48, Ubi-Sara/Sdc10608  SdcDf48  — anti-PLAP in PBT  NGS (from Biomeda in the experiments de-
(maternal/zygotic mutant) scribed here, and used at 1:600; however, new lots of the Biomeda
Sara250   antibody are made against a different antigen [recombinant rather
Fkbp13M34   than placental] and do not work well. In recent experiments we
dally06464   have employed an anti-PLAP rabbit antibody from Serotec at 1:500)
dally80dlpA187   overnight at 4C. The embryo slide was washed in a tray with PBT
trol13   (3 washes; 1 hr total), reblocked, and incubated with goat-anti-
sglA31  — rabbit Alexa488 (Molecular Probes; 1:1000 in PBT NGS). Second-
sfl03844  — ary and tertiary antibodies from 1:10 stocks were preabsorbed in
ttv00681b  — PBT on wild-type fixed embryos to reduce background, then stored
pipe1   at 4CwithNaN3 to prevent bacterial growth. The slideswerewashed
again, visualized tomake sure the staining hadworked, thenwashedlar13.2/lar5.5  
with PBS and cleared with 70% glycerol for 1 hr. Most of the
Other Binding Experiments (Wild-Type Embryos) glycerol was removed after clearing and a coverslip installed. Com-
pound microscope images were obtained with an Olympus cameraLAR-AP  heparin  —
and Magnafire software.EphA3-AP — —
For the deficiency screen, we first balanced the entire Df kit overPLAP — —
GFP balancers. We dissected 4 nongreen embryos and 2 greenLAR-AP  excess PLAP — —
(GFP-balancer) embryos (Df/) in each slide well. The same linesLAR-HS1-AP  —
were simultaneously screened with DPTP69D-AP, so that stainingLAR-HS2-AP  —
with each RPTP-AP provided a control for the other and also indi-
Plus sign indicates normal LAR-AP staining. Minus sign indicates cated whether the line in question formed embryos with enough
absent LAR-AP staining, in either the CNS or muscle attachment structure to allow visualization of staining. mAb BP102 can also be
sites. Most of these entries are discussed in the text. Note that Egfr added at 1:10–1:20 to the secondary antibody to allow simultaneous
deficiencies can only be screened in crosses to proximal deficien- visualization of the axon ladder; BP102 staining is then visualized
cies such as Df(2R)AA21, because removal of Egfr prevents CNS with an antimouse fluorescent secondary antibody.
development. Thus, Df(2R)Egfr5, which is part of the deficiency kit
and removes Sdc, could not be screened directly. The table also
Supplemental Referencesshows that LAR-AP normally to pipe mutants. Pipe is a putative
2-O-sulfotransferase that is implicated in production of specific sul-
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Figure S1. LAR-AP Binding to sfl and dally dlp Embryos, and Bind-
ing Controls
(A) Wild-type (wt) embryo, middle focal plane, showing LAR-AP
staining of CNS axons (arrow).
(B) Wild-type embryo, ventral focal plane, showing LAR-AP staining
of muscle attachment sites (arrows).
(C) sfl03844 (zygotic sfl mutant) embryo, middle focal plane, showing
LAR-AP staining of CNS axons (arrow).
(D) sfl embryo, ventral focal plane. LAR-AP stains the muscle attach-
ment sites to a much lesser extent than with wild-type embryos
(compare to [B]). The dot-like staining pattern is missing, while some
residual lines of staining remain (arrow), much as in Sdc embryos
(Figure 1E).
(E) dally80, dlpA187 embryo (zygotic dally dlp mutant), middle focal
plane, showing LAR-AP staining of CNS axons (arrow).
(F) dally, dlp ventral focal plane, showing LAR-AP staining of muscle
attachment sites (arrow). This LAR-AP staining is indistinguishable
from wt embryos (compare to [B]).
(G) Wild-type embryo incubated with LAR-AP, followed by anti-
PLAP antibody preincubated with excess commercial PLAP. No
signal is detected on the CNS axons (arrow) or at muscle attachment
sites. This experiment demonstrates that the staining pattern ob-
served is dependent on the presence of the human AP epitope on
the embryo via binding of LAR-AP, rather than to cross-reaction of
the secondary or tertiary antibody with a Drosophila epitope.
(H) Wild-type embryo incubated with EphA3-AP (gift of J. Flanagan).
Faint staining in a midline strip is observed (arrow). This pattern
does not resemble the LAR-AP staining pattern.
Scale bar is approximately 10 m. All images were taken with 40
objective and 1.25 ocular at the same exposure settings for com-
parison purposes.
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Figure S2. LAR-AP Binds to Ectopically Ex-
pressed Sdc and Dally Proteins
All images show the ventral muscles span-
ning an abdominal hemisegment on the right
side of a live-dissected stage 16 embryo filet.
Anterior is up. Staining is visualized by immu-
nofluorescence (40 objective). Muscle mor-
phologies look somewhat different with these
stains than when muscles are visualized by
DIC optics. The muscles that are prominent
in these images are labeled in (D) and (F). See
http://www.its.caltech.edu/zinnlab/
motoraxons/muscle%20diagrams.html for a
schematic diagram of muscles. Arrows indi-
cate muscle attachment sites. Arrowheads
indicate muscle fiber edges. Scale bar equals
10 m.
(A) Anti-Sdc staining, wild-type muscles.
(B) LAR-AP staining, wild-typemuscles. Mus-
cle attachment sites (out of focus) stain but
not the muscles.
(C) Anti-Sdc staining of muscles of 24B-GAL4
(muscle driver)  UAS-Sdc embryos (Sdc
overexpression).
(D) LAR-AP staining of muscles of 24B-
GAL4  UAS-Sdc embryos. LAR-AP now
stains muscle edges. Note the dot-like char-
acter of the staining.
(E) Anti-Myc staining of muscles of a UAS-
Dally-Myc control embryo with no driver.
(F) Anti-Myc staining of muscles of a 24B-GAL4  UAS-Dally-Myc embryo (Dally-Myc overexpression). Dally-Myc is now expressed at high
levels on the muscles.
(G) LAR-AP staining of muscles of a 24B-GAL4  UAS-Dally-Myc embryo. Note bright dot-like staining of muscles.
(H) Anti-Dlp staining of muscles of a UAS-Dlp control embryo with no driver. Weak staining is observed at the muscle attachment sites.
(I) Anti-Dlp staining of muscles of a 24B-GAL4  UAS-Dlp embryo (Dlp OE). Dlp is now expressed at high levels in the muscles.
(J) LAR-AP staining of muscles of a 24B-GAL4  UAS-Dlp embryo. Note the lack of bright muscle staining; muscle attachment sites stain
normally. The fact that LAR-AP does not brightly stain Dlp on muscles could indicate that embryonic Dlp lacks some enzymatic modification
required for LAR binding. Alternatively, perhaps the levels of ectopic Dlp attained in our experiments were insufficient to bind enough LAR-
AP for visualization.
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Figure S3. Coimmunoprecipitation of LAR-AP and Sdc
Lane 1: LAR-AP and Sdc-ECD-FLAG (from 293T cells) were incu-
bated together and immunoprecipitated by anti-FLAG mAb. Lane
2: LAR-AP alone immunoprecipitated with anti-FLAG, showing no
cross-reaction of LAR-AP with anti-FLAG. Lane 3: LAR-AP immuno-
precipitated with anti-PLAP, showing the amount of LAR-AP input
and the sizes of the LAR-AP bands. After gel electrophoresis and
transfer, the blot was probed with anti-PLAP. There are three main
species of LAR-AP that are commonly visualized (arrowheads), the
largest of which is 260 kDa; all three precipitate with Sdc-FLAG.
Note the large amount of material at the bottom of lane 3 (bracket);
this is LAR-AP that has been cleaved near the LAR/PLAP junction,
and the PLAP portion is detected on the blot. As expected, this
material does not precipitate with Sdc-FLAG (compare with lane 1).
Figure S4. Additional Genotypes from Genetic Interaction Experi-
ment and Epistasis Experiment
(A) Bar graph showing ISNb bypass phenotypic percentages in
different mutant combinations. Number of abdominal hemiseg-
ments (A2–A7) scored are as follows: Sdc10608  257; SdcDf48  239;
SdcKG06163  191; Larbypass  211 (also in Figure 5); Fkbp13M34  125;
Larbypass, Fkbp13M34  125; Sara250  132; Larbypass, Sara250  233;
dally06464 195; Larbypass; dally06464 83; dally80, dlpA187 230; Larbypass;
dlp1  156; Larbypass; dally80dlpA187  111; ttv00681b  107. This figure
shows that the zygotic Sdc mutants do not display ISNb bypass at
a high penetrance (8%) and that Sara, Fkbp13, dally, and dlp
mutations do not exhibit genetic interactions with Lar, because the
penetrance of the bypass phenotype in all these combinations is
not greater than that seen for Larbypass alone (10%).
(B) Bar graph showing penetrance of SNa phenotypes in various
genetic backgrounds. All SNaswith at least onemissing or obviously
truncated branch were scored as mutant. These results show that
muscle overexpression of Dally produces SNa phenotypes at a low
penetrance (11%, versus 18% for Sdc overexpression; Figure 7);
Dlp overexpression does not produce phenotypes. Number of ab-
dominal hemisegments (A2–A7) scored are as follows: Oregon R 
226; Lar5.5/Lar13.2 138; UAS-Dally-Myc/ 108; G14/; UAS-Dally-
Myc/24B 154;G14/; UAS-Dlp/24B 99. G14 and24B aremuscle
GAL4 drivers; elav is a panneuronal driver.
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Figure S5. LAR and Sdc Localization Are Unchanged in Sdc/Sdc
Maternal/Zygotic Mutants and Lar5.5/Lar13.2 Embryos, Respectively
This experiment demonstrates that the removal of LAR does not
cause a redistribution of Sdc, and vice versa. If a substantial amount
of the Sdc visualized in embryos were cleaved, shed material, and
bound to LAR, one might have expected that Sdc localization would
change in a Larmutant; this is not observed. This figure also shows
LAR localization on CNS axons.
(A) Wild-type (wt) embryo stained with anti-LAR in the absence of
detergent, middle focal plane. Anti-LAR labels the CNS (arrow) and
motor nerves exiting the CNS (arrowheads). The staining of motor
nerves, which only contain a few axons, is very faint, because LAR
is a rare protein. Thus, we could not directly visualize LAR together
with Sdc on motor axons in the periphery. Therefore, in Figure 5 we
used anti-HRP as a marker to visualize the position of the nerves
relative to the patches of Sdc expression.
(B) SdcDf48,ubi-Sara/Sdc10608  SdcDf48 (maternal/zygotic mutant; see
text for description) stained with anti-LAR, middle focal plane. The
expression pattern is indistinguishable from that seen in wild-type
embryos.
(C and D) Lar5.5/Lar13.2 embryo stained with anti-Sdc, middle focal
plane (C) and ventral focal plane (D). The expression pattern is
indistinguishable from wild-type embryos (compare to Figures 1F
and 1G). In the absence of LAR, Sdc is still expressed on the CNS
(arrow [C]) and muscle attachment sites (arrowhead [D]).
Scale bar is approximately 10 m. Images were taken with 40
objective and 1.25 ocular.
